GH-releasing hormone promotes survival and prevents TNF-α-induced apoptosis and atrophy in C2C12 myotubes

Endocrinology (United States)

Volumn 156, Issue 9, 2015, Pages 3239-3252

  Gallo, Davide ^a   Gesmundo, Iacopo ^a   Trovato, Letizia ^a   Pera, Giulia ^a   Gargantini, Eleonora ^a   Minetto, Marco Alessandro ^a   Ghigo, Ezio ^a   Granata, Riccarda ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALPAIN; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE RELEASING FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MUSCLE PROTEIN; MUSCLE RING FINGER1; MYOGENIN; MYOSIN HEAVY CHAIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; HORMONE RECEPTOR; MTOR PROTEIN, MOUSE; NEUROPEPTIDE RECEPTOR; SOMATOTROPIN RELEASING HORMONE RECEPTOR; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL ACTIVATION; CELL DIFFERENTIATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; ENZYME INACTIVATION; ENZYME INHIBITION; MOUSE; MUSCLE ATROPHY; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SKELETAL MUSCLE; ANIMAL; CELL LINE; CYTOLOGY; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; CELL LINE; CELL SURVIVAL; GLYCOGEN SYNTHASE KINASE 3; GROWTH HORMONE-RELEASING HORMONE; MICE; MUSCLE FIBERS, SKELETAL; MUSCLE PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, NEUROPEPTIDE; RECEPTORS, PITUITARY HORMONE-REGULATING HORMONE; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84942804989     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/EN.2015-1098     Document Type: Article

References (57)

1. Schiaffino S, Dyar KA, Ciciliot S, Blaauw B., Sandri M. Mechanisms regulating skeletal muscle growth and atrophy. FEBS J. 2013; 280: 4294-4314.
2. Kandarian SC, Jackman RW Intracellular signaling during skeletal muscle atrophy. Muscle Nerve. 2006; 33:155-165.
3. Egerman MA, Glass DJ Signaling pathways controlling skeletal muscle mass. Crit Rev Biochem Mol Biol. 2014; 49:59-68.
4. Cai D, Frantz JD, Tawa NE Jr, et al. IKKβ/NF-ΚB activation causes severe muscle wasting in mice. Cell. 2004; 119:285-298.
5. Bakkar N, Guttridge DC NF-ΚB signaling: a tale of two pathways in skeletal myogenesis. Physiol Rev. 2010; 90:495-511.
6. Magee P, Pearson S, Allen J. The omega-3 fatty acid, eicosapentaenoic acid (EPA), prevents the damaging effects of tumour necrosis factor (TNF)-α during murine skeletal muscle cell differentiation. Lipids Health Dis. 2008; 7:24.
7. Li YP, Schwartz RJ, Waddell I.D., Holloway BR, Reid MB. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-ΚB activation in response to tumor necrosis factor α. FASEB J. 1998; 12:871-880.
8. Guillemin R. Hypothalamic hormones a.k.a. hypothalamic releasing factors. J Endocrinol. 2005; 184:11-28.
9. Kiaris H, Chatzistamou I, Papavassiliou A.G., Schally AV. Growth hormone-releasing hormone: not only a neurohormone. Trends Endocrinol Metab. 2011; 22:311-317.
10. Frohman LA, Kineman RD Growth hormone-releasing hormone and pituitary development, hyperplasia and tumorigenesis. Trends Endocrinol Metab. 2002; 13:299-303.
11. Pombo CM, Zalvide J, Gaylinn B.D., Dieguez C. Growth hormonereleasing hormone stimulates mitogen-activated protein kinase. Endocrinology. 2000; 141:2113-2119.
12. Granata R, Trovato L, Gallo M.P., et al. Growth hormone-releasing hormone promotes survival of cardiac myocytes in vitro and protects against ischaemia-reperfusion injury in rat heart. Cardiovasc Res. 2009; 83:303-312.
13. Penna C, Settanni F, Tullio F., et al. GH-releasing hormone induces cardioprotection in isolated male rat heart via activation of RISK and SAFE pathways. Endocrinology. 2013; 154:1624-1635.
14. Kanashiro-Takeuchi R.M., Tziomalos K, Takeuchi L.M., et al. Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction. Proc Natl Acad Sci USA. 2010; 107: 2604-2609.
15. Bagno LL, Kanashiro-Takeuchi RM, Suncion V.Y., et al. Growth hormone-releasing hormone agonists reduce myocardial infarct scar in swine with subacute ischemic cardiomyopathy. J Am Heart Assoc. 2015; 4.
16. Kanashiro-Takeuchi R.M., Takeuchi LM, Rick F.G., et al. Activation of growth hormone releasing hormone (GHRH) receptor stimulates cardiac reverse remodeling after myocardial infarction (MI). Proc Natl Acad Sci USA. 2012; 109:559-563.
17. Florea V, Majid SS, Kanashiro-Takeuchi RM, et al. Agonists of growth hormone-releasing hormone stimulate self-renewal of cardiac stem cells and promote their survival. Proc Natl Acad Sci USA. 2014; 111:17260-17265.
18. Rommel C, Bodine SC, Clarke B.A., et al. Mediation of IGF-1-in-duced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol. 2001; 3:1009-1013.
19. Granata R, Gallo D, Luque R.M., et al. Obestatin regulates adipocyte function and protects against diet-induced insulin resistance and inflammation. FASEB J. 2012; 26(8):3393-3411.
20. Annunziata M, Grande C, Scarlatti F., et al. The growth hormonereleasing hormone (GHRH) antagonist JV-1-36 inhibits proliferation and survival of human ectopic endometriotic stromal cells (ESCs) and the T HESC cell line. Fertil Steril. 2010; 94:841-849.
21. Granata R, Settanni F, Trovato L., et al. RFamide peptides 43RFa and 26RFa both promote survival of pancreatic β-cells and human pancreatic islets but exert opposite effects on insulin secretion. Diabetes. 2014; 63:2380-2393.
22. Walsh K, Perlman H. Cell cycle exit upon myogenic differentiation. Curr Opin Genet Dev. 1997; 7:597-602.
23. Dirks AJ, Leeuwenburgh C. Tumor necrosis factor α signaling in skeletal muscle: effects of age and caloric restriction. J Nutr Biochem. 2006; 17:501-508.
24. Langen RC, Schols AM, Kelders M.C., Wouters EF, Janssen-Heininger YM. Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-κB. FASEB J. 2001; 15: 1169-1180.
25. Miller SC, Ito H, Blau H.M., Torti FM. Tumor necrosis factor inhibits human myogenesis in vitro. Mol Cell Biol. 1988; 8:2295-2301.
26. Schally AV, Varga JL, Engel JB Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab. 2008; 4:33-43.
27. Manning BD, Cantley LC AKT/PKB signaling: navigating downstream. Cell. 2007; 129:1261-1274.
28. Buck M, Chojkier M. Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants. EMBOJ. 1996; 15:1753-1765.
29. Tolosa L, Morla M, Iglesias A., Busquets X, Llado J, Olmos G. IFN-7 prevents TNF-α-induced apoptosis in C2C12 myotubes through down-regulation of TNF-R2 and increased NF-αB activity. Cell Signal. 2005; 17:1333-1342.
30. Cooper RN, Tajbakhsh S, Mouly V., Cossu G, Buckingham M, Butler-Browne GS. In vivo satellite cell activation via Myf5 and MyoD in regenerating mouse skeletal muscle. J Cell Sci. 1999; 112(Pt 17): 2895-2901.
31. Smith IJ, Lecker SH, Hasselgren PO Calpain activity and muscle wasting in sepsis. Am J Physiol Endocrinol Metab. 2008; 295:E762-E771.
32. Andrianjafiniony T, Dupre-Aucouturier S, Letexier D., Couchoux H, Desplanches D. Oxidative stress, apoptosis, and proteolysis in skeletal muscle repair after unloading. Am J Physiol Cell Physiol. 2010; 299:C307-C315.
33. Bodine SC, Latres E, Baumhueter S., et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 2001; 294: 1704-1708.
34. Schakman O, Dehoux M, Bouchuari S., et al. Role of IGF-I and the TNFα/NF-κB pathway in the induction of muscle atrogenes by acute inflammation. Am J Physiol Endocrinol Metab. 2012; 303:E729-E739.
35. Granata R, Isgaard J, Alloatti G., Ghigo E. Cardiovascular actions of the ghrelin gene-derived peptides and growth hormone-releasing hormone. Exp Biol Med (Maywood). 2011; 236:505-514.
36. Matsubara S, Sato M, Mizobuchi M., Niimi M, Takahara J. Differential gene expression of growth hormone (GH)-releasing hormone (GRH) and GRH receptor in various rat tissues. Endocrinology. 1995; 136:4147-4150.
37. Christodoulou C, Schally AV, Chatzistamou I, et al Expression of growth hormone-releasing hormone (GHRH) and splice variant of GHRH receptors in normal mouse tissues. Regul Pept. 2006; 136: 105-108.
38. Havt A, Schally AV, Halmos G, et al The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues. Proc Natl Acad Sci USA. 2005; 102:17424-17429.
39. Barabutis N, Schally AV Growth hormone-releasing hormone: extrapituitary effects in physiology and pathology. Cell Cycle. 2010; 9:4110-4116.
40. Pommier SA, Dubreuil P, Pelletier G., Gaudreau P, Mowles TF, Brazeau P. Effect of a potent analog of human growth hormonereleasing factor on carcass composition and quality of crossbred market pigs. J Anim Sci. 1990; 68:1291-1298.
41. Li YP, Reid MB NF-ΚB mediates the protein loss induced by TNF-α in differentiated skeletal muscle myotubes. Am J Physiol Regul Integr Comp Physiol. 2000; 279:R1165-R1170.
42. Chen S, Guttridge DC, Tang E, Shi S., Guan K, Wang CY. Suppression of tumor necrosis factor-mediated apoptosis by nuclear factor κB-independent bone morphogenetic protein/Smad signaling. J Biol Chem. 2001; 276:39259-39263.
43. Phillips T, Leeuwenburgh C. Muscle fiber specific apoptosis and TNF-α signaling in sarcopenia are attenuated by life-long calorie restriction. FASEB J. 2005; 19:668-670.
44. Sishi BJ, Engelbrecht AM Tumor necrosis factor α (TNF-α) inactivates the PI3-kinase/PKB pathway and induces atrophy and apoptosis in L6 myotubes. Cytokine. 2011; 54:173-184.
45. Segard HB, Moulin S, Boumard S., Augier de Cremiers C, Kelly PA, Finidori J. Autocrine growth hormone production prevents apoptosis and inhibits differentiation in C2C12 myoblasts. Cell Signal. 2003; 15:615-623.
46. Isgaard J, Nilsson A, Vikman K., Isaksson OG. Growth hormone regulates the level of insulin-like growth factor-I mRNA in rat skeletal muscle. J Endocrinol. 1989; 120:107-112.
47. Sadowski CL, Wheeler TT, Wang LH, Sadowski HB. GHregulation of IGF-I and suppressor of cytokine signaling gene expression in C2C12 skeletal muscle cells. Endocrinology 2001; 142:3890-3900.
48. Bowers CY, Granda R, Mohan S., Kuipers J, Baylink D, Veldhuis JD Sustained elevation ofpulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women. J Clin Endocrinol Metab. 2004; 89:2290-2300.
49. Yamamoto D, Ikeshita N, Matsubara T., et al. GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasoneinduced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1. Life Sci. 2008; 82:460-466.
50. Dimauro I, Magi F, La Sala G, Pittaluga M, Parisi P., Caporossi D. Modulation of the apoptotic pathway in skeletal muscle models: the role of growth hormone. Growth Factors. 2011; 29:21-35.
51. Cai R, Schally AV, Cui T, et al Synthesis of new potent agonistic analogs of growth hormone-releasing hormone (GHRH) and evaluation of their endocrine and cardiac activities. Peptides. 2014; 52: 104-112.
52. Stitt TN, Drujan D, Clarke B.A., et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell. 2004; 14:395-403.
53. Bodine SC, Stitt TN, Gonzalez M, et al Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol. 2001; 3:1014-1019.
54. Cross DA, Alessi DR, Cohen P, Andjelkovich M., Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995; 378:785-789.
55. Pansters NA, Schols AM, Verhees K.J., et al. Muscle-specific GSK-3β ablation accelerates regeneration of disuse-atrophied skeletal muscle. Biochim Biophys Acta. 2014; 1852:490-506.
56. Verhees KJ, Schols AM, Kelders M.C., Op den Kamp CM, van der Velden JL, Langen RC. Glycogen synthase kinase-3 β is required for the induction of skeletal muscle atrophy. Am J Physiol Cell Physiol. 2011; 301:C995-C1007.
57. Sandri M, Sandri C, Gilbert A., et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 2004; 117:399-412.